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Introduction
Lung cancer is the biggest cancer killer in Europe. Non-small-
cell lung cancer (NSCLC) accounts for the vast majority of
cases. The annual number of newly diagnosed patients in
Europe exceeds 200 000, accounting for  20% of all cancer
deaths, and on average 28% of male cancer deaths across the
continent [1, 2]. In females, lung cancer accounts for 10% of
deaths. Five-year survival is 9.6%, ranging from 5.9% in
Denmark to 16.2% in Switzerland [3].
Despite these figures and the fact that screening is an
accepted strategy in invasive cancers with similar incidence
but lesser mortality and better survival than lung cancer, e.g.
breast, colorectal and prostate cancer, screening in lung cancer
is not routinely advocated. The introduction of low-dose spiral
computed tomography (LD-SCT) has reopened the debate.
The present status of lung cancer screening will be reviewed
here.
For cancer registration and treatment reasons, a lung cancer
diagnosis should be confirmed whenever possible. The various
methods of obtaining a tissue diagnosis and their accuracy
will be reviewed.
Screening
The primary aim of cancer screening is to decrease its mor-
tality at a population level. This implies that the tumor is
detected when a therapeutic intervention is likely to influence
the clinical evolution, provided such an effective treatment is
available. This interaction between screening and treatment is
the source of biased expectations with regard of the true
screening effect. The ratio of lung cancer deaths to population
screened is the only reliable and unbiased estimator of the
effect of screening. Survival after diagnosis is a biased estima-
tor of the screening effect, as screening is associated with the
diagnosis.
A screening tool should preferably not harm, neither itself,
nor by the occurrence of false positives generating extra costs,
anxiety and stress. In addition, screening should be cost-
effective in a society perspective, and avoid burdening the
already strained public health expenditures.
Up to now, two screening methods have been studied in
randomized controlled trials: chest X-ray and sputum cytologi-
cal examination (Table 1) [4–9].One non-randomized con-
trolled trial and six randomized controlled trials, including a
total of 245 610 persons, were reported and included in a
recent meta-analysis [10]. Another is still ongoing [11]. In all
studies, the control group received at least some type of
screening at baseline and/or at the end of the study. Ran-
domization is hence to be considered between more or less
frequent screening. More frequent screening with chest radio-
graphy was associated with an 11% relative increase in mor-
tality from lung cancer compared with less frequent screening
[risk ratio (RR) 1.11; 95% confidence interval (CI)
1.00–1.23], suggesting that frequent chest radiography might
even be harmful. A non-statistically significant trend towards
reduced mortality from lung cancer was observed when
screening with chest radiography and sputum cytological
examination was compared with chest radiography alone (RR
0.88; 95% CI 0.74–1.03). The 5-year survival rate of patients
diagnosed with lung cancer was better in the more often
screened group, with a combined RR of death from lung
cancer of 0.91 (95% CI 0.84–0.99; P = 0.02). Several of the
studies included had potential methodological weaknesses and
were powered to detect an unrealistic 50% decrease in lung
cancer mortality. The study population consisted furthermore
of male smokers only. With females becoming an increasing
fraction of lung cancer patients with an independent prognos-
tic importance, results of studies in males might not be necess-
arily extrapolated to the female population. Although survival
is improved, the current evidence does not support screening
for lung cancer with chest radiography or sputum cytological
examination. However, recent narrative reviews have drawn
conflicting conclusions [12–14]. Furthermore, newer screen-
ing methods have now been proposed, such as LD-SCT.
Low-dose spiral computed tomography scanning
The development of CT scanning technology reopens the lung
cancer screening debate [15]. The introduction of spiral scan-
ning techniques with helical reconstruction algorithm has
further improved the spatial resolution over conventional CT
scans. The latter were hampered by single slice techniques and
breathing artifacts [16, 17]. Present day fourth-generation mul-
tislice (up to 64 detectors) spiral CT scan apparatus delivers a
radiation dose approaching that of a chest radiograph and
inferior to mammography (50 mAs). No intravenous contrast
material is administered. Images covering the entire lung
region can be acquired in a single breath-hold at end-inspiration
(12 s), following hyperventilation, and are reconstructed at
overlapping 3-mm intervals. Images are viewed at so-called
lung and mediastinal windows [width 1600 Hounsfield
units (HU), level 650 HU; width 325 HU, level 25 HU,
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respectively] [15]. Computer-aided diagnosis techniques record
characteristics such as size, location, texture and pattern of cal-
cification, and allow data analysis according to a preset algor-
ithm, minimizing inter- and intra-observer variability.
The use of multislice spiral CT has lowered the detection
threshold for pulmonary nodules to 1–3 mm, without an
increase in radiation dose and with less respiration artifacts
[16, 17]. Sensitivity for nodules >1 cm is estimated at 95%
and for nodules <1 cm 91%, but this high sensitivity comes at
the cost of a decreased specificity. A non-calcified pulmonary
nodule (NPN) is identified if it does not show a benign pattern
of calcification. These are observed in 10% to 50% of screened
subjects from the risk population [15, 18–22]. Most NPN
<8 mm are benign. The likelihood of malignancy increases
with size, approximating 50% in one series of NPN >20 mm
[19]. Lung cancers are diagnosed in between 0.9% and 2.7%
of screened subjects. LD-SCT hence detects more lung can-
cers in an earlier ‘asymptomatic’ stage than do conventional
chest X-rays: 0.48% versus 0.03% to 0.05% (Table 2).
Typically, >_70% of the tumors are in stage IA, as compared
with <10% in patients with symptoms. As stage is the stron-
gest predictor of survival, the latter has been repeatedly shown
to be improved in patients detected by screening.
Multiple reasons may explain why a large number of earlier
stage tumors does not necessarily result in improved lung can-
cer mortality. Lead-time bias is caused by the diagnosis of
Table 1. Randomized trials evaluating screening in lung cancer
Study (study population)
[Ref.]
Intervention and control No. of
participants
Number of cancers
at prevalence screen
Number of cancers
at incidence screen
Lung cancer
mortality
Absolute Per 1000
persons
Absolute Per 1000
persons
Absolute Per 1000
persons
London (males >40
years) [4]
Chest X-ray every 6 months for
3 years
29 723 31 1.0 101 NA 62 2.1
Chest X-ray after 3 years 25 311 20 0.8 76 NA 59 2.4
Total 55 034 51 0.9 177 NA 121 2.2
MSKC-LCSP (smoking
males >45 years) [5]
Chest X-ray and sputum every
4 months; follow-up for 5–8 years
4968 30 6.0 114 3.7 74 2.7
Yearly chest X-ray and sputum;
follow-up for 5–8 years
5072 23 4.5 121 3.8 82 2.7
Total 10 040 53 5.3 235 3.75 156 2.7
JHLP (smoking males
>45 years) [6]
Chest X-ray and sputum every
4 months for 4.5 years
5226 39 7.5 194 NA NA 3.4
Yearly chest X-ray and sputum
for 4.5 years
5161 40 7.8 202 NA NA 3.8
Total 10 386 79 7.6 396 NA NA 2.7
MLP (smoking males
>45 years) [7]
Chest X-ray and sputum every
4 months for 6 years
4618 NA NA 206 5.5 122 3.2
Advice: yearly chest X-ray and sputum 4593 NA NA 160 4.3 115 3.0
Total 10 933 91 8.3 366 NA 237 NA
Czech study (smoking males
>40–64 years) [8, 9]
Chest X-ray and sputum every
6 months for 3 years
3172 NA NA 39 NA 19 3.6
Chest X-ray and sputum after
3 years
3174 NA NA 27 NA 13 2.6
Total 6364 18 2.8 66 NA .32 NA
MSKC-LCSP, Memorial Sloan-Ketttering Cancer Center Lung Cancer Screening Project; JHLP, Johns Hopkins Lung Project; MLP, Mayo Lung Project;
NA, not available.
Table 2. Summary of the Japanese Anti-Lung Cancer Association experience (1975–2002) [23]
Screening tool/time period No. cases
studies
Histology (%) Stage (%) Mean diameter peripheral-type
lung cancers (cm)
Cancer detection
rate (%)
5-year overall
survival (%)
AD SQ SC IA III/IV
Chest X-ray and sputum
cytology 1975–1993
26 338 49 35 12 42 33 3.0 0.16 49
LD-SCT 1993–2002 15 342 63 30 3 78 14 1.5 0.41 84
AD, adeno; SQ, squamous; SC, small cell; LD-SCT, low-dose spiral computed tomography.
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cancers detected by screening in an asymptomatic patient.
The increased survival reflects the interval between diagnosis
by screening and first symptoms. Length-time bias occurs
when slow-growing tumors are detected, which have a longer
survival. To avoid this bias, observation after screening should
be sufficiently long. Overdiagnosis bias implies that the indi-
vidual in whom cancer is detected was destined to die of a
competing cause before the cancer would have resulted in
symptoms and been clinically detected [24]. This does not
mean that the cancer is not a true cancer, or that its histology
is not similar to other types of invasive cancers. Overdiagnosis
is inevitable for lung cancer screening, as the majority of the
cancers develop in current or former heavy cigarette smokers.
A heavy smoker loses 10 years of life expectancy on average
because of diseases caused by smoking; one-fifth of these are
lung cancers, but the other four-fifths are competing causes of
death (largely cardiac, some respiratory), and these are the
reasons for death in overdiagnosed cases.
Controlled studies of spiral CT scanning have not been
reported. Japanese data suggest the superiority of LD-SCT
over chest X-ray in detecting early and potentially curative
lung cancer. A number of recently published series across
three continents support a benefit of LD-SCT in detecting
earlier stage NSCLC (Table 3).
Although different imaging and management approaches
have been used, they achieve fairly consistent results. The
challenge of the most efficient diagnostic work-up has also
been highlighted in a recent paper on cost-effectiveness [25].
Non-invasive case validation was associated with a lower
overall cost compared with more frequent invasive case
validation. Another issue is the management of spurious and
incidental findings (aortic aneurysm, emphysema, other
cancers) [19].
The influence of LD-SCT on lung cancer mortality is cur-
rently being studied in several large screening trials in Europe
and the USA [27]. In the Dutch–Belgian NELSON trial,
randomization is being carried out in 24 000 at-risk men and
women between active smoking cessation with or without
annual LD-SCT for 4 years. No baseline screening is
performed in the control arm. The National Lung Cancer
Screening Trial (NLST) in the USA is randomizing 50 000
persons at-risk between annual conventional chest X-ray and
annual LD-SCT for 3 years. In an Italian study proposal,
randomization will be between between yearly and every
second year screening with LD-SCT for 10 years, with or
without PET scan. Similar Danish and French pilot studies are
planned, randomizing between LD-SCT and chest X-ray or no
screening, respectively. Most of these trials aim at a lung can-
cer mortality reduction of 50% in the screened population.
The results of these trials will not be available for 5–10 years.
New developments in screening
Sputum immunocytology promises much greater sensitivity
than conventional sputum cytology: experiments with the
monoclonal antibody 703D4 have shown that overexpression
of hnRNP A2/B1, an RNA-binding protein, is a powerful
predictor of early subclinical cancer in high-risk groups [28].
An alternative approach is based on photometric measure-
ments of >100 features such as shape and texture extracted
from the nucleus of epithelial cells found in sputum. Using
these features, the cells are automatically classified into differ-
ent cell types, associated with different risk pattern for devel-
oping lung cancer. This method of automated quantitative
cytometry (AQC) reduces costs, improves the intra- and inter-
observer variability, and is currently in the process of being
validated (Perceptronix Medical, Vancouver, Canada) [29].
Analysis of circulating DNA in plasma can provide a useful
marker for early lung cancer detection. In a study assessing
the sensitivity and specificity of a quantitative molecular assay
of circulating DNA to identify patients with lung cancer and
monitor their disease, the median concentration of circulating
plasma DNA in patients was almost eight times the value
detected in controls [30]. This suggests that plasma DNA
elevation is a strong risk factor for lung cancer [31].
(Auto-)fluorescence bronchoscopy uses the property of
(pre-)neoplastic mucosa to differentially reflect incoming
Table 3. Summary of pilot LD-SCT screening results for NSCLC
Institution/reference No. of
subjects
% patients
with NPN
No. of CT-detected
lung cancers
Mean/median primary
cancer size (mm)
Frequency of detecting
post-surgical stage I tumors (%)
Cornell (prevalence) [15] 1000 23 27 14/<_ 10 0.85
Cornell (incidence) [18] 1000 NA 7 12/8 0.71
Mayo Clinic (prevalence) [19] 1520 51 29 NA NA
Mayo Clinic (incidence) [19] 1000 NA 21 NA NA
National Cancer Center
(prevalence) [20]
1611 11.5 14 20/20 0.79
National Cancer Center
(incidence) [21]
770 NA 22 15/20 0.82
Milan (prevalence) [22] 1035 29 11 21/NA 0.55
Milan (incidence) [22] 996 NA 11 15/NA 1.00
LD-SCT, low-dose spiral computed tomography; NSCLC, non-small-cell lung cancer; NPN, non-calcified pulmonary nodule; CT, computed tomography;
NA, not available.
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monochromatic light, based on differences in mucosal
thickness and intracellular molecules. Although most experts
agree on its high sensitivity compared with classic white-light
bronchoscopy, its low specificity and the invasiveness of
the procedure precludes its role as a widespread screening
tool. Its potential use is as a case-finder in individuals found
to have abnormalities on sputum screen techniques [32].
Sputum immunocytology, AQC and plasma DNA measure-
ments may have their optimal use in ‘prescreening’ individ-
uals for LD-SCT. A preliminary study using AQC, CT
scanning and autofluorescence bronchoscopy showed that
AQC of sputum cells improved the detection rate of lung
cancer [33]. Further research is ongoing.
Diagnosis
In most cancer registries, tissue diagnosis of lung cancer
diagnosis is required and is documented in more than 80% to
90% of patients [34]. Histological proof is obtained for up to
77% of cases, and only cytology in 17%. NSCLC represents
 80% of lung cancer cases, with squamous cell lung cancer
still preceding adenocarcinoma in relative frequency in most
European series [35]. The latter subtype is, however, increas-
ing, mostly in women and non-smoking cases. In 1999, the
WHO adopted a new classification of lung cancer [36].
Standard light microscopy with hematoxylin–eosin stains is
sufficient for histological diagnosis in most cases of NSCLC.
Periodic acid–Schiff and immunohistochemical stains are
necessary in only a few histological types and for differentia-
ting subtypes of adenocarcinoma and neuro-endocrine sub-
types. Morphological separation of NSCLC and small-cell
lung cancer (SCLC) can be difficult even for experienced
pathologists. Disagreement among the latter over the distinc-
tion may occur in up to 5% to 7% of cases [27]. Morphologi-
cal subclassification of NSCLC remains imprecise. Agreement
on subtype classification of adenocarcinoma occurs in only
40% of samples. Histological heterogeneity, the presence of a
mixture of histological types representing a manifestation of
the derivation of lung cancer from a pluripotent stem cell, is
an important reason. It is hence appropriate to use the term
NSCLC in small tissue specimens when it is not possible to
be certain about the subtype. This heterogeneity is responsible
for the observed differences between pathological diagnosis in
biopsy and resection specimens. Special considerations apply
in the case of a presumed diagnosis of lung cancer, synchrone
or metachrone to another solid cancer. In these cases, special
stains and even molecular techniques will be necessary to rule
out any relationship with the other tumor [37].
Guidelines regarding reliable diagnosis of lung cancer have
recently been published [38, 39]. Whenever possible, a tissue
diagnosis of cancer obtained from a suspected metastasis has
the advantage of proving not only the malignant character of
the tumor, but also its invasiveness and dissemination.
Lung cancer presents with a various clinical picture and is
disseminated at first diagnosis in >40% of cases [34]. Despite
this, first diagnosis is obtained most often by sampling of
intrathoracic structures or tissues. Only the techniques
involved in the latter will be reviewed here.
Flexible bronchoscopy
Flexible bronchoscopy is an essential part in the diagnosis of
a patient with presumed lung cancer, because it is diagnostic
in >70% of cases [40]. The procedure can be performed in an
outpatient setting and is safe when performed by experienced
hands. A number of simple techniques are available to obtain
the diagnosis of endoscopically visible lesions during the pro-
cedures: bronchial biopsy, brushing and sputum aspiration are
mostly used. The top part of Table 4 shows a comparison of
the average diagnostic yield of the different procedures. The
pooled sensitivity of these histological and cytological tech-
niques in case of centrally located tumors is 89% [40]. Maxi-
mal results are obtained when four to five biopsies are taken.
In cases of peripherally located tumors or extrabronchial
enlarged lymph nodes, other techniques are available requiring
a more skilled physician: broncho-alveolar lavage, transbron-
chial biopsy and/or fine needle aspiration (TBNA). The latter
two are preferably carried out under fluoroscopic guidance.
The lower part of Table 4 shows a comparison of the average
diagnostic yield of the different procedures. Pooled sensitivity
of flexible bronchoscopy techniques in case of a peripheral
tumor is 69%. Ideally, six to 10 specimens should be obtained
for optimal diagnostic yield. If the lesion is <2 cm diameter
the diagnostic accuracy is only 33%, and CT-guided puncture
is far more preferable (see below). Although rapid on-site
evaluation (ROSE) seems to improve the diagnostic yield of
TBNA, its cost-effectiveness remains unclear.
Cytological examination of sputum is preferably reserved to
patients whose general condition precludes a bronchoscopy.
Table 4. Diagnostic yield of individual bronchoscopic procedures for
endoscopically visible lung cancers and peripheral cancers
Procedure No. of
patients
Diagnosis Average diagnostic
yield (%)
Range
(%)
Endoscopically visible lung cancers
BW 1535 1041 68 27–90
BR 1578 1131 72 44–94
EBB 1934 2418 80 51–97
EBNA 456 365 80 68–91
Peripheral cancers
BW 704 196 28 4–43
BR 1174 528 45 6–83
BAL 225 136 60 33–69
TBB 1509 786 52 13–83
TBNA 792 473 60 40–69
Adapted from Mazzone et al. [40].
BW, bronchial washing; BR, bronchial brushing; EBB, endobronchial
biopsy; EBNA, endobronchial needle aspiration; BAL, broncho-alveolar
lavage; TBB, transbronchial biopsy; TBNA, transbronchial needle
aspiration.
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Its sensitivity is 71% for central and 49% for peripheral
tumors [40].
Transthoracic needle techniques
Advances in needle technology have improved safety and
increased the accuracy of transthoracic needle biopsy (TNB).
Needles vary according to size, tip design and sampling mech-
anism. Small gauge aspiration needles provide specimens suit-
able for cytological evaluation. Small- or large-bore cutting
needles are capable of providing histology samples. The
choice of needle relates to the location of the lesion, the
amount of tissue required for a diagnosis and the operator’s
comfort. Studies comparing cutting with aspiration needles
have demonstrated a similar or lower yield for malignant
lesions for the former, but a higher yield for specific benign
diagnoses and lymphoma, with little increase in complications
[40]. Sensitivity for the diagnosis of peripheral primary lung
cancer by TNB is 90%. The yield depends on the size of the
lesion, and is highest in lesions with a diameter >2 cm and
lower for smaller lesions (95% and 78%, respectively). CT
guidance has a higher sensitivity than fluoroscopic guidance
(92% versus 88%). The most frequent complication is pneu-
mothorax, occurring in approximately one out of four patients.
In only 5% to 10% of these, thoracic drainage is required.
Bleeding is the second most common complication, occurring
in  5% of patients, and is almost always self-limited; there
have been sporadic reports of needle tract implantation of
tumor cells [41].
Thoracentesis
With 35% of cases, lung cancer is the most frequent cause of
malignant pleural fluid [42]. In 7% to 10% of patients with
lung cancer, malignant pleural fluid will be a presenting fea-
ture or will develop during the course of disease. Not every
case of pleural fluid is necessarily malignant. Paramalignant
effusions occur, and can be due to obstructive pneumonitis,
paraneoplastic pulmonary embolism, chylothorax or transu-
dates caused by cardiogenic or hypoproteinaemic comorbidity.
The presence of malignant cells in pleural fluid classifies the
tumor as T4, hence at least stage IIIB, and not amenable to
radical treatment [34]. Pleural fluid visible on chest X-ray of a
lung cancer patient should be analyzed by thoracentesis of at
least 30 ml of fluid. Its diagnostic yield depends of the extent
of pleural involvement and ranges from 62% to 90%.
Repeated thoracentesis and concentration techniques, e.g. cell
block preparation, increases the sensitivity [43]. The majority
of malignant effusions are detected with two specimens [44].
Examination of more than three specimens is of little value.
Through the utilization of cell block preparations and a panel
of antibodies appropriate for the differential diagnosis in ques-
tion, immunocytochemistry conditions utilized in surgical
pathology can be most closely replicated [45]. In those cases
still negative after two thoracenteses and in whom radical
treatment is considered, a thoracoscopy should be performed
to inspect closely and biopsy the pleural cavity [38].
New developments in the diagnosis
of lung cancer
A number of new and innovative techniques in association
with conventional bronchoscopic procedures are being deve-
loped to improve the diagnostic yield of flexible broncho-
scopy. Among these are the bronchoscopic ultrasonography,
esophageal ultrasonography with fine-needle aspiration with
ROSE, and virtual bronchoscopy-guided transbronchial needle
aspiration [40]. Their application awaits further validation in
prospective series.
Finally, gene expression profiling techniques will provide
further improvements in the present light-microscopical classi-
fication by identifying subsets with discrete molecular charac-
teristics [46].
Conclusions
Screening for lung cancer in risk groups with sputum
cytology, chest X-ray or spiral CT scan is not advised until a
definite reduction in lung cancer mortality is shown to occur
in the screened group. Patients should be taught to seek medi-
cal advice in case of a change in coughing pattern, hemoptysis
or dyspnea. Their physicians should unrelentingly continue
their smoking cessation advice and be aware that lung cancer
also occurs in ex-smokers presenting with these symptoms.
Once a presumed diagnosis is made, tissue diagnosis is to
be pursued, even if treatment options are bleak at first glance.
Modern endoscopic and transthoracic puncture techniques are
highly accurate in experienced hands and have an acceptable
morbidity and a low mortality. When confronted with a non-
diagnostic procedure or a peripheral lung lesion with high
a priori suspicion of cancer, pretreatment tissue diagnosis
should only be pursued if the latter will impact on treatment.
The decision to continue with diagnostic procedures hence
depends on whether or not a radical treatment can be offered
and sustained.
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